Shuling Zhang

1.7k total citations
75 papers, 1.2k citations indexed

About

Shuling Zhang is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Shuling Zhang has authored 75 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Oncology, 24 papers in Pulmonary and Respiratory Medicine and 15 papers in Immunology. Recurrent topics in Shuling Zhang's work include Lung Cancer Treatments and Mutations (15 papers), Lung Cancer Research Studies (13 papers) and Lung Cancer Diagnosis and Treatment (9 papers). Shuling Zhang is often cited by papers focused on Lung Cancer Treatments and Mutations (15 papers), Lung Cancer Research Studies (13 papers) and Lung Cancer Diagnosis and Treatment (9 papers). Shuling Zhang collaborates with scholars based in China, United States and Somalia. Shuling Zhang's co-authors include Beverly A. Mock, Cheng‐Bo Han, Jie‐Tao Ma, Le‐Tian Huang, Edward S. Ramsay, Li Sun, Fengping Shan, Junli Guo, Dan Qi and Shaojiang Zheng and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Blood.

In The Last Decade

Shuling Zhang

70 papers receiving 1.2k citations

Peers

Shuling Zhang
Shisuo Du China
Jingjing Zhao China
Dorina Gui United States
Alexandr V. Bazhin Germany
Ronald Chan Hong Kong
Kazuhito Funai Japan
Yaomin Xu United States
Yu Gu China
Afşar Barlas United States
Shisuo Du China
Shuling Zhang
Citations per year, relative to Shuling Zhang Shuling Zhang (= 1×) peers Shisuo Du

Countries citing papers authored by Shuling Zhang

Since Specialization
Citations

This map shows the geographic impact of Shuling Zhang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shuling Zhang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shuling Zhang more than expected).

Fields of papers citing papers by Shuling Zhang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shuling Zhang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shuling Zhang. The network helps show where Shuling Zhang may publish in the future.

Co-authorship network of co-authors of Shuling Zhang

This figure shows the co-authorship network connecting the top 25 collaborators of Shuling Zhang. A scholar is included among the top collaborators of Shuling Zhang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shuling Zhang. Shuling Zhang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Baechler, Simone A., Anjali Dhall, Hongliang Zhang, et al.. (2025). Topoisomerase III-beta protects from immune dysregulation and tumorigenesis. Science Advances. 11(51). eady7028–eady7028.
2.
Ma, Jie‐Tao, Jun S. Song, Xiaofang Yi, et al.. (2024). Enhanced T cell immune activity mediated by Drp1 promotes the efficacy of PD-1 inhibitors in treating lung cancer. Cancer Immunology Immunotherapy. 73(2). 40–40. 4 indexed citations
3.
Zhang, Shuling, Li Sun, Le‐Tian Huang, et al.. (2024). Targeting mitochondria: restoring the antitumor efficacy of exhausted T cells. Molecular Cancer. 23(1). 260–260. 23 indexed citations
4.
5.
6.
Huang, Hai, et al.. (2023). In vitro and in vivo killing effects of methionine enkephalin on osteosarcoma. International Immunopharmacology. 125(Pt B). 111226–111226. 5 indexed citations
7.
8.
Huang, Le‐Tian, Shuling Zhang, Cheng‐Bo Han, & Jie‐Tao Ma. (2022). Impact of EGFR exon 19 deletion subtypes on clinical outcomes in EGFR-TKI-Treated advanced non-small-cell lung cancer. Lung Cancer. 166. 9–16. 24 indexed citations
9.
10.
Zhang, Shuling, et al.. (2021). The role of elevated red blood cell distribution width in the prognosis of AECOPD patients. Medicine. 100(10). e25010–e25010. 8 indexed citations
11.
Zhang, Shuling, et al.. (2021). Methionine enkephalin (MENK) suppresses lung cancer by regulating the Bcl-2/Bax/caspase-3 signaling pathway and enhancing natural killer cell-driven tumor immunity. International Immunopharmacology. 98. 107837–107837. 27 indexed citations
12.
Huang, Hai, et al.. (2021). Research progress of opioid growth factor in immune-related diseases and cancer diseases. International Immunopharmacology. 99. 107713–107713. 8 indexed citations
13.
Sun, Li, Yijia Guo, Jun Song, et al.. (2021). Neoadjuvant EGFR-TKI Therapy for EGFR-Mutant NSCLC: A Systematic Review and Pooled Analysis of Five Prospective Clinical Trials. Frontiers in Oncology. 10. 586596–586596. 48 indexed citations
14.
Gary, Joy, John K. Simmons, Jinfei Xu, et al.. (2020). Hypomorphic mTOR Downregulates CDK6 and Delays Thymic Pre-T LBL Tumorigenesis. Molecular Cancer Therapeutics. 19(10). 2221–2232. 8 indexed citations
15.
Zhang, Shuling, et al.. (2020). Biological effects of IL-15 on immune cells and its potential for the treatment of cancer. International Immunopharmacology. 91. 107318–107318. 53 indexed citations
16.
Huang, Le‐Tian, Jie‐Tao Ma, Shuling Zhang, et al.. (2019). Durable Clinical Response to Pyrotinib After Resistance to Prior Anti-HER2 Therapy for HER2-Positive Advanced Gastric Cancer: A Case Report. Frontiers in Oncology. 9. 1453–1453. 15 indexed citations
17.
Ma, Jie‐Tao, Xiangyan Zhang, Rui Cao, et al.. (2019). Effects of Dynamin-related Protein 1 Regulated Mitochondrial Dynamic Changes on Invasion and Metastasis of Lung Cancer Cells. Journal of Cancer. 10(17). 4045–4053. 23 indexed citations
18.
Zhang, Shuling, et al.. (2017). Benefits of postoperative thoracic radiotherapy for small cell lung cancer subdivided by lymph node stage: a systematic review and meta-analysis. Journal of Thoracic Disease. 9(5). 1257–1264. 5 indexed citations
19.
20.
Zhang, Shuling & Beverly A. Mock. (1999). The Role of p16INK4a (Cdkn2a) in Mouse Plasma Cell Tumors. Current topics in microbiology and immunology. 246. 363–368. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shisuo Du Breakdown of academic impact, for papers by Jingjing Zhao Breakdown of academic impact, for papers by Dorina Gui Breakdown of academic impact, for papers by Alexandr V. Bazhin Breakdown of academic impact, for papers by Ronald Chan Breakdown of academic impact, for papers by Kazuhito Funai Breakdown of academic impact, for papers by Yaomin Xu Breakdown of academic impact, for papers by Yu Gu Breakdown of academic impact, for papers by Afşar Barlas
Rankless by CCL
2026